GlassScriptPhysician profile
Nicholas C Bechtold
NPI 1932493749
$3,485.59
in general payments reported to CMS, 2019-2025
36 companies · $746 in 2025
The $746 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $312 · 2021: $500 · 2022: $398 · 2023: $663 · 2024: $630 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,016 · Education: $23.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,015.57 |
| Education | $23.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $746.08 | 2021-2025 | |
| Abbvie INC. | $653.85 | 2021-2025 | Ubrelvy, Linzess, Viberzi |
| Novo Nordisk INC | $528.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $256.37 | 2024-2025 | Farxiga, Breztri |
| Amgen INC. | $238.84 | 2019-2022 | |
| Amarin Pharma, INC. | $166.32 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $91.75 | 2023-2024 | Keveyis |
| Merck Sharp & Dohme LLC | $91.18 | 2021-2023 | Belsomra |
| Lilly USA, LLC | $74.30 | 2022-2025 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.59 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $61.82 | 2024-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $60.90 | 2025 | |
| Abbott Laboratories | $58.78 | 2022-2023 | Freestyle Libre 3 |
| Seqirus USA INC | $35.37 | 2024 | Flucelvax, Fluad |
| Genzyme Corporation | $28.20 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $27.89 | 2025 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $25.56 | 2022 | |
| Daiichi Sankyo INC. | $25.12 | 2020-2021 | |
| Eisai INC. | $23.89 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $23.52 | 2021 | |
| Abiomed | $19.87 | 2024 | Impella |
| Dexcom, INC. | $19.76 | 2024 | Dexcom G6 Transmitter |
| Krystal Biotech INC | $17.72 | 2024 | Vyjuvek |
| Astellas Pharma US INC | $16.24 | 2020 | |
| Mallinckrodt Hospital Products INC. | $14.38 | 2025 | Acthar |
| Ultragenyx Pharmaceutical INC. | $14.30 | 2021 | |
| Impel Pharmaceuticals INC. | $13.24 | 2023 | Trudhesa |
| Hologic Sales and Service, LLC | $13.20 | 2021 | |
| Mylan Specialty L.P. | $13.13 | 2021 | |
| Allergan, INC. | $12.90 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.42 | 2021 | |
| Sanofi Pasteur INC. | $11.32 | 2019 | |
| Glaxosmithkline, LLC. | $11.12 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.10 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Bechtold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.